Century Therapeutics (IPSC) Operating Leases (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Operating Leases data on file, last reported at $43.9 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 8.06% year-over-year to $43.9 million in Q1 2026; TTM through Mar 2026 was $43.9 million, a 8.06% decrease from a year earlier, with the FY2025 full-year figure at $40.2 million, down 17.81% from the prior year.
• Operating Leases for Q1 2026 stood at $43.9 million, up from $40.2 million in the prior quarter.
• Over the last five years, Operating Leases for IPSC reached as high as $52.7 million in Q2 2024 and fell as low as $14.4 million in Q1 2022.
• Historically, Operating Leases has averaged $41.8 million across 5 years, with a median of $43.9 million in 2026.
• Across the five-year window, Operating Leases jumped 185.29% in 2023 and fell 18.99% in 2025, its largest moves.
• Year by year, Operating Leases stood at $38.7 million in 2022, then grew by 20.57% to $46.7 million in 2023, then grew by 4.93% to $49.0 million in 2024, then declined by 17.81% to $40.2 million in 2025, then rose by 9.2% to $43.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $43.9 million in Q1 2026, $40.2 million in Q4 2025, and $41.2 million in Q3 2025.